<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003517</url>
  </required_header>
  <id_info>
    <org_study_id>BC-PR-6</org_study_id>
    <secondary_id>CDR0000066560</secondary_id>
    <nct_id>NCT00003517</nct_id>
  </id_info>
  <brief_title>Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer</brief_title>
  <official_title>Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burzynski Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the&#xD;
      laboratory. Antineoplastons may inhibit the growth of cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating&#xD;
      patients with stage III or stage IV prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of antineoplastons A10 and AS2-1 capsules in&#xD;
           combination with total androgen blockade in patients with localized, regional or&#xD;
           metastatic adenocarcinoma of the prostate by determining the proportion of patients who&#xD;
           experience an objective tumor response.&#xD;
&#xD;
        -  Evaluate the adverse effects of and tolerance to this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive gradually escalating doses of antineoplastons A10 and AS2-1 capsules orally&#xD;
      6-7 times daily until the maximum tolerated dose is reached. Treatment continues for at least&#xD;
      3 months in the absence of disease progression or unacceptable toxicity. Concurrently,&#xD;
      patients continue hormonal therapy with flutamide, leuprolide, or bicalutamide at the same&#xD;
      dose as before beginning antineoplaston therapy.&#xD;
&#xD;
      Tumors are measured every 4 months for 2 years, every 6 months for 2 years, and then annually&#xD;
      for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Stage III Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antineoplaston A10</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antineoplaston AS2-1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>alternative product therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiandrogen therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biologically based therapies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cancer prevention intervention</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>complementary and alternative therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>differentiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hormone therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven localized, regional, or metastatic adenocarcinoma of the&#xD;
             prostate&#xD;
&#xD;
          -  Progressive disease during prior hormonal therapy (both antiandrogen and&#xD;
             gonadotropin-releasing hormone) and must continue hormonal therapy&#xD;
&#xD;
          -  Measurable tumors or tumor markers&#xD;
&#xD;
          -  Bone metastases allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No hepatic failure&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No chronic renal failure&#xD;
&#xD;
          -  BUN less than 60 mg/dL&#xD;
&#xD;
          -  Creatinine no greater than 2.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  Blood ammonia normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe lung disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  No serious active infections or fever&#xD;
&#xD;
          -  No other prior or concurrent second malignancy within the past 2 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational clinical trial&#xD;
&#xD;
          -  No other concurrent treatment for metastatic prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislaw R. Burzynski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Burzynski Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burzynski Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055-6330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Androgen Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

